Ignite Creation Date:
2025-12-24 @ 11:45 PM
Ignite Modification Date:
2026-01-10 @ 4:15 PM
Study NCT ID:
NCT00591851
Status:
COMPLETED
Last Update Posted:
2023-09-25
First Post:
2007-12-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2004-12
Start Date Type:
None
Primary Completion Date:
2008-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2008-06
Completion Date Type:
ACTUAL
First Submit Date:
2007-12-26
First Submit QC Date:
None
Study First Post Date:
2008-01-11
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2014-11-24
Results First Submit QC Date:
None
Results First Post Date:
2014-12-01
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-11
Last Update Post Date:
2023-09-25
Last Update Post Date Type:
ACTUAL